{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-205522","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2025-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.463692+00:00","generated_at":"2026-05-17T06:22:10.135890+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elicio reports 99% T cell response rate in Phase 2 AMPLIFY-7P trial of ELI-002 7P","bullets":["ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90).","Average fold increase 145.3x over baseline; median 44.3x; 80% of patients above 9.5x threshold correlated with clinical activity in Phase 1.","85% of patients had combined CD4+CD8 T cell response vs 75% in Phase 1; 67.4% responded to all 7 mKRAS antigens vs 50%.","IDMC recommended continue without modifications after interim safety/efficacy review; company remains blinded to clinical outcomes.","Final disease-free survival analysis anticipated in Q4 2025; Phase 2 includes both MRD+ and MRD- patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-205522","json":"https://secwatch.observer/filing/0001193125-25-205522.json","markdown":"https://secwatch.observer/filing/0001193125-25-205522.md","text":"https://secwatch.observer/filing/0001193125-25-205522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000119312525205522/0001193125-25-205522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000119312525205522/d38971d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:22:10.135890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}